KFDA Communicates Potential Safety Risks with Atopic Dermatitis Treatments
Published: 2005-03-18 06:57:00
Updated: 2005-03-18 06:57:00
The Korea Food and Drug Administration (KFDA) made a communication on the potential safety risks that are associated with pimecrolimus and tacrolimus, both which are indicated for treatment of atopic dermatitis (AD), in its March 16th Dear Healthcare Professional Letter.
The letter advises not...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
